My Recent Searches
- No Recent Search.
My Tests Viewed
- No Test Viewed.
PD-L1 Non-Lung (Pembrolizumab), IHC (New)
- Ordering Info
To view specimen requirements and codes please Select a regional laboratory.Not sure which laboratory serves your office? Call us 866-MYQUEST (866-697-8378)
**IMPORTANT: CPT Code is informational only; obtain the Test Code for ordering.
See Laboratory Report
PD-L1 IHC 22C3 pharmDx is indicated as an aid in identifying patients for treatment with KEYTRUDA® (Pembrolizumab). This FDA approved test currently is applicable only to adenocarcinomas of gastric or gastro-esophageal junction origin.
For non-FDA approved test indications or sample types, order 94007-PD-L1, IHC with Interpretation.
For other FDA approved primary tumors, please order the following:
For NSCLC order 93279-PD-L1 Lung (Pembrolizumab), IHC, 93359-PD-L1 Lung (Nivolumab), IHC or 94480-PD-L1 Lung (Atezolizumab), IHC; for urothelial bladder carcinoma order 94047-PD-L1 Bladder (Atezolizumab), IHC; and for melanoma order 93793-PD-L1 Melanoma (Nivolumab), IHC.
PDL1,Keytruda,Dako test PD-L1 IHC 22C3pharmDx™,PDL-1
Reference ranges are provided as general guidance only. To interpret test results use the reference range in the laboratory report.
The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.
* The tests listed by specialist are a select group of tests offered. For a complete list of Quest Diagnostics tests, please refer to our Directory of Services.